Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging

Affiliations

¹ Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. giovanni.paganelli@irst.emr.it.
² Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
³ Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Comment

Giovanni Paganelli et al. Eur J Nucl Med Mol Imaging. 2017 Sep.

. 2017 Sep;44(10):1777-1778.

doi: 10.1007/s00259-017-3682-8. Epub 2017 Mar 22.

¹ Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. giovanni.paganelli@irst.emr.it.
² Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
³ Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

No abstract available

Comment on

Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with ¹⁷⁷Lu-D OTATATE.
Sansovini M, Severi S, Ianniello A, Nicolini S, Fantini L, Mezzenga E, Ferroni F, Scarpi E, Monti M, Bongiovanni A, Cingarlini S, Grana CM, Bodei L, Paganelli G. Sansovini M, et al. Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):490-499. doi: 10.1007/s00259-016-3533-z. Epub 2016 Oct 4. Eur J Nucl Med Mol Imaging. 2017. PMID: 27704193
Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging.
Zanotti-Fregonara P, Morgat C, Champion C, Hindié E. Zanotti-Fregonara P, et al. Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1095-1096. doi: 10.1007/s00259-017-3667-7. Epub 2017 Mar 10. Eur J Nucl Med Mol Imaging. 2017. PMID: 28283701 No abstract available.